Paper - WANFANG MED ONLINE

You Position: Home > Paper

Immunotherapy for mantle cell lymphoma

( views:541, downloads:417 )

Author:: No author available

Journal Title:: JOURNAL OF LEUKEMIA & LYMPHOMA

Issue:: 1

DOI:: 10.3760/cma.j.issn.1009-9921.2008.01.001

Key Word:: 淋巴瘤,膜细胞;免疫疗法;放射免疫疗法;移植物抗淋巴瘤反应;供者淋巴细胞输注

Abstract：套细胞淋巴瘤(MCL)是一种恶性侵袭性非霍奇金淋巴瘤,以出现t(11;14)(q13;q32)以及细胞周期蛋白D1(Cyclin D1)过度表达为特征,预后很差.近年来,生物学、遗传学以及免疫学的发展推动了MCL的免疫治疗.单用利妥昔单抗的疗效有限,但将其与其他化疗方案如CHOP(环磷酰胺联合多柔比星、长春新碱、泼尼松)、hyperCVAD/MTX-Ara-C(高剂量环磷酰胺联合长春新碱、多柔比星、地塞米松与甲氨蝶呤或阿糖胞苷交替)、FCM(氟达拉滨联合环磷酰胺、米托蒽醌)等联合之后,无论作为MCL的一线治疗还是挽救治疗,疗效均有明显改善.利妥昔单抗用于维持治疗或与自体造血干细胞移植联合后可延长缓解持续时间.此外,替伊莫单抗以及妥司莫单抗、异基因造血干细胞移植、供者淋巴细胞输注、树突状细胞、独特型疫苗联合等,其他的免疫治疗如沙利度胺和雷利度胺联合利妥昔单抗在复发性或难治性MCL中也取得了一定进展.

Reference

[1]D.T. Nguyen,J. A. Amess,H. Doughty,etc.IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients[J].1999,62(2).
[2]Longo DL,Bendandi M,Sternas LA,etc.Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma (see comments)[J].1999,5(10).
[3]McLaughlin P,Acholonu S,Younes A,etc.Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.[J].2003,21(23).
[4]Munger CM,Joshi SS,Vose JM.Dendritic cell-based therapy for mantle cell lymphoma.[J].2006,28(6).
[5]Roswitha, Forstpointner,Martin, Dreyling,Roland, Repp,etc.The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell [J].2004,104(10).
[6]Sarris AH,Younes A,Pro B,etc.High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.[J].2005,23(28).
[7]Jacobsen E,Freedman A.An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.[J].2004,16(2).
[8]Welslau M,Rost A,Hecker R,etc.Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma.[J].2005,23(15).
[9]G, Damaj,F, Lefrère,R, Delarue,etc.Thalidomide therapy induces response in relapsed mantle cell lymphoma.[J].2003,17(9).
[10]Choi E,Adams J,Zelenetz AD,etc.Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.[J].2005,23(4).
[11]Ritz J,Freedman AS,Mauch P,etc.High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission (see comments)[J].1998,16(1).
[12]Mels, Hoogendoorn,Judith, Olde Wolbers,Willem M, Smit,etc.Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation.[J].2005,11(14).
[13]Matthews J,Foran JM,Coiffier B,etc.Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.[J].2000,11(Suppl.1).
[14]Lenz G,Aldaoud A,Parwaresch R,etc.Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: resu[J].2005,23(9).
[15]Crump Michael,Richardson Patricia,Robinson JeanB,etc.Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.[J].2002,29(1 Suppl.2).
[16]Norris D,Grigg A,Bashford J,etc.Autografting followed by rituximab for chemosensitive mantle cell lymphoma: A pilot study and literature review.[J].2005,46(6).
[17]Lee D,Hunter T,Noyes D,etc.A GM-CSF/CD40L producing cell augments anti-tumor T cell responses.[J].2005,125(2).
[18]Reyes F,Gaulard P,Farcet JP,etc.Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.[J].2004,15(3).
[19]Witzig TE,Geyer SM,Ghobrial I,etc.Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.[J].2005,23(23).
[20]John M, Timmerman,Debra K, Czerwinski,Thomas A, Davis,etc.Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.[J].2002,99(5).
[21]Djulbegovic B,Robertson MJ,Lonial S,etc.Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.[J].2006,24(30).
[22]Hannes, Kaufmann,Markus, Raderer,Stefan, W?hrer,etc.Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma.[J].2004,104(8).
[23]Huber C,Kolbe K,Derigs HG,etc.Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.[J].2003,31(9).
[24]Michael B, Maris,Brenda M, Sandmaier,Barry E, Storer,etc.Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.[J].2004,104(12).
[25]Neelapu SS,Kwak LW,Kobrin CB,etc.Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.[J].2005,11(9).
[26]Russell NH,Byrne JL,Faulkner RD,etc.Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.[J].2005,36(5).
[27]John P, Leonard,Richard R, Furman,Jia, Ruan,etc.New developments in immunotherapy for non-Hodgkin's lymphoma.[J].2005,7(5).
[28]Cortelazzo S,Magni M,Martelli M,etc.Rituximab: enhancing stem cell transplantation in mantle cell lymphoma.[J].2002,29(Suppl.1).
[29]Lamy T,de Guibert S,Turlure P,etc.Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma.[J].2006,91(3).
[30]Brugger W,Vogel W,Fehnle K,etc.Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.[J].2004,15(11).
[31]B, Coiffier,C, Haioun,N, Ketterer,etc.Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.[J].1998,92(6).